Khaled Hussein, Abu-Taleb Fouad, Haggag Rasha
Medical Oncology Department, National Cancer Institute, Cairo University, Cairo 11796, Egypt.
Medical Oncology Department, Faculty of Medicine, Zagazig University, Zagazig 44519, Egypt.
J Adv Res. 2017 Mar;8(2):131-137. doi: 10.1016/j.jare.2016.11.005. Epub 2016 Dec 12.
B-cell NHL is strongly associated with HCV that was proved in the last 2 decades. The most common HCV infection related B-NHL subtypes include MZL and DLBCL lymphomas. HCV-positive NHL patients usually present with older age at diagnosis, higher LDH, and more extranodal disease. The standard chemo-immunotherapy tolerance is generally good. Antiviral treatment achieves virological and hematological remission in HCV associated indolent lymphoma. More aggressive lymphoma requires combination of antiviral treatment and chemotherapy. New generation of HCV antiviral drugs is safe and is highly efficacious. Regimens including DAAs appear promising options as they can reduce the HCV-associated NHL incidence by dramatically lowering the HCV chronic carriers.
在过去20年中已证实，B细胞非霍奇金淋巴瘤（NHL）与丙型肝炎病毒（HCV）密切相关。最常见的与HCV感染相关的B-NHL亚型包括黏膜相关淋巴组织淋巴瘤（MZL）和弥漫性大B细胞淋巴瘤（DLBCL）。HCV阳性的NHL患者通常在诊断时年龄较大，乳酸脱氢酶（LDH）较高，且结外病变较多。标准的化疗免疫疗法耐受性一般良好。抗病毒治疗可使HCV相关的惰性淋巴瘤实现病毒学和血液学缓解。侵袭性更强的淋巴瘤则需要抗病毒治疗与化疗相结合。新一代HCV抗病毒药物安全且高效。包括直接抗病毒药物（DAAs）在内的治疗方案似乎是很有前景的选择，因为它们可以通过大幅减少HCV慢性携带者来降低HCV相关NHL的发病率。
